{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(1)"],"submitter":["Droitcourt C"],"funding":["French Ministry of Social Affairs and Health, France"],"pubmed_abstract":["<h4>Background</h4>Atopic dermatitis is a highly prevalent, chronic, relapsing disease in both adults and children. On the severity spectrum, lower-end patients benefit from small amounts of topical anti-inflammatory treatments (TAT), whereas higher-end patients need systemic immunosuppressants; in-between patients are treated with TAT and phototherapy. The major therapeutic challenge in this population is the long-term control of disease activity, and the current TAT-based pro-active strategy does not meet all their needs. Immunosuppressants are used as long-term control add-on treatments, but they are restricted to the most severely affected patients because of safety concerns. In addition, neither immunosuppressants nor other strategies have been properly evaluated in the long term desp"],"journal":["Trials"],"pagination":["184"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6434814"],"repository":["biostudies-literature"],"pubmed_title":["A new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D supplementation, for the long-term control of atopic dermatitis: study protocol for a multicentre, randomized, crossover, pragmatic trial - the PRADA trial."],"pmcid":["PMC6434814"],"pubmed_authors":["Weiborn M","Oger E","Seneschal J","Darrieux L","Plantin P","Barbaud A","Soria A","Vermersch A","Groupe de Recherche sur l’Eczéma Atopique de la Société Française de Dermatologie (GREAT)","Misery L","Phan A","Brenaut E","Staumont-Salle D","Droitcourt C","Taieb A","Adamski H","Chabbert C","Dupuy A","Maruani A","Viguier M","Skowron F","Nosbaum A","Barbarot S","Maillard H"],"additional_accession":[]},"is_claimable":false,"name":"A new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D supplementation, for the long-term control of atopic dermatitis: study protocol for a multicentre, randomized, crossover, pragmatic trial - the PRADA trial.","description":"<h4>Background</h4>Atopic dermatitis is a highly prevalent, chronic, relapsing disease in both adults and children. On the severity spectrum, lower-end patients benefit from small amounts of topical anti-inflammatory treatments (TAT), whereas higher-end patients need systemic immunosuppressants; in-between patients are treated with TAT and phototherapy. The major therapeutic challenge in this population is the long-term control of disease activity, and the current TAT-based pro-active strategy does not meet all their needs. Immunosuppressants are used as long-term control add-on treatments, but they are restricted to the most severely affected patients because of safety concerns. In addition, neither immunosuppressants nor other strategies have been properly evaluated in the long term desp","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Mar","modification":"2026-05-03T12:14:50.354Z","creation":"2019-06-05T15:44:38Z"},"accession":"S-EPMC6434814","cross_references":{"pubmed":["30909923"],"doi":["10.1186/s13063-019-3276-9"]}}